{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:26:14Z","timestamp":1789010774820,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow (BM). Despite the significant advances in treatment, relapsed and refractory MM has not yet been completely cured due to the immune dysfunction in the tumor microenvironment (TME). In this study, we analyzed the transcriptome data from patients with newly diagnosed (ND) and relapsed\/refractory (R\/R) MM to characterize differences in the TME and further decipher the mechanism of tumor progression in MM. We observed highly expressed cancer testis antigens and immune suppressive cell infiltration, such as Th2 and M2 cells, are associated with MM progression. Furthermore, the TGF-\u03b2 signature contributes to the worse outcome of patients with R\/R MM. Moreover, patients with ND MM could be classified into immune-low and immune-high phenotypes. Immune-high patients with higher IFN-g signatures are associated with MHC-II\u2013mediated CD4+ T-cell response through CIITA stimulation. The baseline TME status could potentially inform new therapeutic choices for the ND MM who are ineligible for autologous stem cell transplantation and may help predict the response to CAR-T for patients with R\/R MM. Our study demonstrates how integrating tumor transcriptome and clinical information to characterize MM immune microenvironment and elucidate potential mechanisms of tumor progression and immune evasion, which will provide insights into MM treatment selection.<\/jats:p>","DOI":"10.3389\/fonc.2022.948548","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T11:12:23Z","timestamp":1660302743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling"],"prefix":"10.3389","volume":"12","author":[{"given":"Jin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Punnoose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"B5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","article-title":"Incidence and mortality of multiple myeloma in China, 2006-2016: An analysis of the global burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1038\/s41467-020-16434-y","article-title":"Evolution and structure of clinically relevant gene fusions in multiple myeloma","volume":"11","author":"Foltz","year":"2020","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/s41467-017-00638-w","article-title":"Expressed fusion gene landscape and its impact in multiple myeloma","volume":"8","author":"Cleynen","year":"2017","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.08.001","article-title":"Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression","volume":"47","author":"Yang","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B24","first-page":"9","article-title":"Expression of cancer\/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease","volume":"3","author":"Dhodapkar","year":"2003","journal-title":"Cancer Immun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.037978","article-title":"Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy","volume":"96","author":"van Duin","year":"2011","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","article-title":"KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment","volume":"78","author":"Dias Carvalho","year":"2018","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4161\/org.25676","article-title":"Macrophages and CSF-1: Implications for development and beyond","volume":"9","author":"Jones","year":"2013","journal-title":"Organogenesis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/183602","article-title":"Multiple myeloma macrophages: Pivotal players in the tumor microenvironment","volume":"2013","author":"Berardi","year":"2013","journal-title":"J Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09943-1","article-title":"Macrophages in multiple myeloma: Key roles and therapeutic strategies","volume":"40","author":"Opperman","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jmcb\/mjr033","article-title":"TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells","volume":"4","author":"Tran","year":"2012","journal-title":"J Mol Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of normal and myelomatous plasma-cell subsets","volume":"5","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP63TOCFNAMDMS","article-title":"The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: A new statistical model","volume":"137","author":"Cannizzo","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.01.009","article-title":"MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma","volume":"44","author":"Zhao","year":"2007","journal-title":"Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"key":"B39","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1760","article-title":"VEGF induces mcl-1 up-regulation and protects multiple myeloma cells against apoptosis","volume":"104","author":"Le Gouill","year":"2004","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in b-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627764","article-title":"Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: Prospects for personalized management and prognostic prediction","volume":"12","author":"Hong","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2405-7","article-title":"Immunopathogenesis and immunotherapy of multiple myeloma","volume":"107","author":"Tamura","year":"2018","journal-title":"Int J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of adaptive T cell immunity in multiple myeloma: Insights into mechanisms and therapeutic opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/196063","article-title":"Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes","volume":"2012","author":"Rutella","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hon.704","article-title":"T Cells in myeloma","volume":"21","author":"Raitakari","year":"2003","journal-title":"Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04984.x","article-title":"Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma","volume":"125","author":"Brown","year":"2004","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.948548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T11:12:32Z","timestamp":1660302752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.948548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":47,"alternative-id":["10.3389\/fonc.2022.948548"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.948548","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"article-number":"948548"}}